RVV — Revive Therapeutics Share Price
0.000.00%
Last trade - 00:00- CA$12.56m
- CA$12.00m
- 26
- 39
- 17
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.32 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45.74% | ||
| Return on Equity | -45.13% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
Directors
- Michael Frank CHM
- Carmelo Marrelli CFO
- Joshua Herman IND
- William Jackson IND
- Andrew Lindzon IND
- Christian Scovenna IND
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 27th, 2012
- Public Since
- July 12th, 2013
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 418,564,269
- Address
- 82 Richmond Street East, TORONTO, M5C 1P1
- Web
- https://revivethera.com/
- Phone
- +1 9056055535
- Auditors
- CLEARHOUSE LLP
Upcoming Events for RVV
Similar to RVV
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
FAQ
What is the Revive Therapeutics share price?
As of Today at 19:18 UTC, shares in Revive Therapeutics are trading at CA$0.03. This share price information is delayed by 15 minutes.
How has the Revive Therapeutics share price performed this year?
Shares in Revive Therapeutics last closed at CA$0.03 and the price had moved by -64.71% over the past 365 days. In terms of relative price strength the Revive Therapeutics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -66.51% over the past year.
What are the analyst and broker recommendations for Revive Therapeutics?
There is no consensus recommendation for this security.
What is the Revive Therapeutics dividend yield?
Revive Therapeutics does not currently pay a dividend.
Does Revive Therapeutics pay a dividend?
Revive Therapeutics does not currently pay a dividend.
When does Revive Therapeutics next pay dividends?
Revive Therapeutics does not currently pay a dividend.
How do I buy Revive Therapeutics shares?
To buy shares in Revive Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Revive Therapeutics?
As of the previous close price of CA$0.03, shares in Revive Therapeutics had a market capitalisation of CA$12.56m.
Where are Revive Therapeutics shares listed?
Here are the trading details for Revive Therapeutics:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: RVV
What kind of share is Revive Therapeutics?
Based on an overall assessment of its quality, value and momentum Revive Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Revive Therapeutics share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Revive Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Revive Therapeutics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -25.14%.
As of the last closing price of CA$0.03, shares in Revive Therapeutics were trading -10.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Revive Therapeutics PE Ratio?
The Revive Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Revive Therapeutics?
Revive Therapeutics' management team is headed by:
- Michael Frank - CHM
- Carmelo Marrelli - CFO
- Joshua Herman - IND
- William Jackson - IND
- Andrew Lindzon - IND
- Christian Scovenna - IND